


What is claimed :

1. A compound having the molecular structure :

5



wherein R₃ is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and a moiety $-C\equiv CR'$ (R' being hydrogen or C1-C6 lower alkyl);

- 10 wherein R₄ is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and cyanide;

wherein R_{17α} is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl, or R_{17α} and R_{17β} together are oxygen forming a keto group;


- 15 wherein R_{17β} is selected from the group consisting of hydroxyl and a group transformed on the skin into hydroxyl, or R_{17α} and R_{17β} together are oxygen forming a keto group;

wherein R_{16α} is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;


- 20 wherein R_{16β} is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;

wherein at least one of R₃ or R₄ is not an hydrogen.

2. The compound selected from the group consisting of :


4-cyano-16 α -methyl-16 β -ethyl-1,3,5(10)-estratrien-17 β -ol

and

4-cyano-16 α -methyl-16 β -ethyl-1,3,5(10)-estratrien-17-one

5

3. A pharmaceutical composition comprising a pharmaceutical acceptable diluent or carrier and a therapeutically acceptable amount of an antiandrogen having
- 10 the molecular structure :



wherein R_3 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and a moiety $-C\equiv CR'$ (R' being hydrogen or C1-C6 lower alkyl);

- 5 wherein R_4 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and cyanide;

wherein $R_{17\alpha}$ is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl, or $R_{17\alpha}$ and $R_{17\beta}$ together are oxygen forming a keto group;


- 10 wherein $R_{17\beta}$ is selected from the group consisting of hydroxyl and a group transformed on the skin into hydroxyl, or $R_{17\alpha}$ and $R_{17\beta}$ together are oxygen forming a keto group;

wherein $R_{16\alpha}$ is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;


- 15 wherein $R_{16\beta}$ is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;

wherein at least one of R_3 , or R_4 is not an hydrogen.

4. A pharmaceutical composition comprising a pharmaceutical acceptable
20 diluent or carrier and a therapeutically acceptable amount of an antiandrogen selected from the group consisting of :

4-cyano-16 α -methyl-16 β -ethyl-1,3,5(10)-estratrien-17 β -ol

and

4-cyano-16 α -methyl-16 β -ethyl-1,3,5(10)-estratrien-17-one

5

5. A method of treating or reducing the risk of developing, acne, seborrhea, hirsutism or androgenic alopecia, comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of the compound of claim 1

10

6. The method of claim 5, further comprising administering to said patient a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase

15

7. The method of claim 5, further comprising administering to said patient a therapeutically effective amount of a 5 α -reductase inhibitor.

8. The method of Claim 5, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).

9. The method of Claim 6, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).

10

10. The method of claim 7, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).

11. The method of claim 5, further comprising administering to said patient a therapeutically effective amount of a 5 α -reductase inhibitor and an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase.

12. The method of Claim 11, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).